|
Nov 23, 2022
|
AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
|
|
|
Nov 08, 2022
|
AC Immune to Present at the Jefferies London Healthcare Conference
|
|
|
Oct 28, 2022
|
AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
|
|
|
Oct 04, 2022
|
AC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome
|
|
|
Sep 26, 2022
|
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into Late-stage Development in Alzheimer’s Disease
|
|
|
Sep 01, 2022
|
AC Immune Receives a Grant from The Michael J. Fox Foundation for Continued Development of Parkinson’s Disease Diagnostic Imaging Agent
|
|
|
Aug 24, 2022
|
AC Immune KOL Webinar on the Potential Benefits of Vaccines for Alzheimer’s and Parkinson’s Diseases
|
|
|
Aug 11, 2022
|
AC Immune to Host Key Opinion Leader Webinar on Vaccinations to Treat and Prevent Alzheimer’s and Parkinson’s Diseases
|
|
|
Aug 02, 2022
|
Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented at AAIC
|
|
|
Jul 28, 2022
|
AC Immune Reports Second Quarter 2022 Financial Results and Provides Corporate Update
|
|